It is possible for funders to buy innovation, but it requires a different approach than funding ongoing services. Why innovate? Funding services or innovation, not both (PDF)
Tag Archive for Druglink
Druglink article 1999 – Touchy subject, explosive matter: volatile substance abuse by Keith Owen
Solvent abuse kills more young people than ecstasy, the law tries to restrict supply but what about service provision? Touchy subject, explosive matter: volatile substance abuse (PDF)
Druglink article 1999 – Positively negative: drug testing uncovered by Claire Meadway, Shashi Parmar and Steve George
Understanding the laboratory approach to drugs testing answers many questions surrounding the results Positively negative: drug testing uncovered (PDF)
Druglink article 2013 – An eye on the children by Joy Barlow
An eye on the children (PDF) Joy Barlow, one of the initiators of the Hidden Harm report, on what has has been learned and what remains to be done Hidden Harm was a seminal report from the Advisory Council of the Misuse of Drugs…
Druglink article 2013 – A noxious business
When teenager Sophie smoked a legal brand of synthetic cannabis she expected to get high. But it turned out to be a nasty experience that the sellers and websites promoting the brand refused to acknowledge A noxious business (PDF)
Druglink interview 2013 – Vivienne Evans OBE by Harry Shapiro
Ten years ago, the ACMD published Hidden Harm a landmark report on the impact of parental drug use on children. We asked Vivienne Evans OBE, Chief Executive of Adfam, to what extent children’s lives have been improved since. Interview: Vivienne Evans OBE (PDF) Additional keywords: parents…
Druglink news item 2013 – Mad about Molly by Max Daly
This summer a series of deaths of young people after taking the party drug Molly shocked America’s resurgent rave scene. Mad about Molly (PDF)
Druglink/DrugWatch factsheet 2013 – Potent synthetic cannabinoid smoking mixtures
The market for synthetic cannabinoid smoking mixtures (sometimes called ‘spice’, ‘synthetic cannabis’ or ‘noids’) is well established, although UK prevalence is still largely unknown. The vast majority of the market is made up of pre-packaged branded products. These branded products contain a nonpsychoactive dried plant base that has been…
Druglink article 2013 – Vapour Trials Revisited by Deborah Arnott
In a response to Clive Bates’ comment piece in the last issue of Druglink, Deborah Arnott of Action on Smoking and Health (ASH) argues that proper regulation of e-cigarettes is needed if they are to become truly effective and widely accepted, while not allowing…
Druglink article 2013 – The end of the road by Neil McKeganey
Neil McKeganey argues that there should be standards or guidance to help determine how long drug treatment, whether a medical or psychological intervention, should continue. The world of UK drug treatment is being influenced by two big ideas that, to an extent, are pulling…